Last reviewed · How we verify
NCT03908957
to Assess the Safety of Ga68-Dolacga Injection in Healthy Volunteers
Phase 1 trial testing Ga68-Dolacga Injection in Safety Issues in 12 participants. Completed in 9 August 2019.
9 August 2019
Quick facts
| Lead sponsor | National Atomic Research Institute, Taiwan |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 12 |
| Start date | 12 February 2019 |
| Primary completion | 9 August 2019 |
| Estimated completion | 9 August 2019 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Ga68-Dolacga Injection — full drug profile →
Conditions studied
- Safety Issues — all drugs for Safety Issues →
Sponsor
National Atomic Research Institute, Taiwan
Who can join
20 and older, any sex, with Safety Issues. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase 1 study to evaluate the safety of Ga68-Dolacga Injection in healthy volunteers and to assess the normal reference range and inter-individual variability of the Ga68-Dolacga Injection in estimating liver reserve in healthy volunteers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03908957
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ga68-Dolacga Injection
Trials testing the same drug.
- NCT05007548 — to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography · Phase 2 · completed
Other recruiting trials for Safety Issues
Currently open trials in the same condition.
- NCT06485141 — BeSMART Secure Storage Counseling in the Inpatient Setting · NA · recruiting
- NCT06494527 — A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults · Phase 1 · active not recruiting
- NCT06189170 — Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients · EARLY_PHASE1 · recruiting
- NCT06509490 — NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors · NA · recruiting
- NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting
Other National Atomic Research Institute, Taiwan trials
Trials by the same sponsor.
- NCT06182865 — A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy · NA · unknown
- NCT05007548 — to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03908957 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Atomic Research Institute, Taiwan
- Last refreshed: 13 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03908957.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing